Asian Pacific Journal of Cancer Prevention

  • 제17권3호
  • /
  • Pages.1449-1452
  • /
  • 2016
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Treatment Outcome and Predictors of Survival in Thai Adult Rhabdomyosarcoma Cases

  • Sookprasert, Aumkhae (Division of Medical Oncology, Internal Medicine Department, Faculty of Medicine, Khon Kaen University) ;
  • Ungareewittaya, Piti (Department of Pathology, Faculty of Medicine, Khon Kaen University) ;
  • Manotepitipongse, Areesa (Division of Medical Oncology, Internal Medicine Department, Faculty of Medicine, Khon Kaen University) ;
  • Wirasorn, Kosin (Division of Medical Oncology, Internal Medicine Department, Faculty of Medicine, Khon Kaen University) ;
  • Chindaprasirt, Jarin (Division of Medical Oncology, Internal Medicine Department, Faculty of Medicine, Khon Kaen University)
  • 발행 : 2016.04.11
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: Adult rhabdomyosarcoma (RMS) is a rare and aggressive disease with limited data compared with pediatric RMS. The goal of this study was to determine the treatment outcome and identify factors related to survival outcome in Thailand. Materials and Methods: Adult patients (${\geq}15$ years old) with the pathological diagnosis of RMS between 1985 and 2010 were reviewed. The data were retrospectively reviewed from the pathological results and medical records from Srinagarind Hospital, Khon Kaen University. Results: A total of 34 patients were identified in the study. The median age at diagnosis was 35.5 years and the most common primary sites were extremity and the head and neck region. The incidence of pleomorphic RMS increased with age and none was found in those aged younger than 20 years old. The median survival time was 9.33 months (95%CI: 5.6-13.1). The 1- and 5- year survival rates were 38.2% (22.3-54.0) and 20.6% (9.1-35.3). On multivariate analysis, age and size of tumor did not predict better outcome while chemotherapy and surgery were significantly associated with longer survival. Conclusions: Outcome of adult RMS was poor. Surgery and chemotherapy are strongly associated with better prognosis and multimodality treatment should be incorporated in the clinic.

키워드

참고문헌

  1. Ariel IM, Briceno M (1975). Rhabdomyosarcoma of the extremities and trunk: analysis of 150 patients treated by surgical resection. J Surg Oncol, 7, 269-87. https://doi.org/10.1002/jso.2930070403
  2. Arndt CA, Hawkins DS, Meyer WH, et al (2008). Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer, 50, 33-6. https://doi.org/10.1002/pbc.21093
  3. Arndt CA, Stoner JA, Hawkins DS, et al (2009). Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803. J Clin Oncol, 27, 5182-8. https://doi.org/10.1200/JCO.2009.22.3768
  4. Esnaola NF, Rubin BP, Baldini EH, et al (2001). Response to chemotherapy and predictors of survival in adult rhabdomyosarcoma. Ann Surg, 234, 215-23. https://doi.org/10.1097/00000658-200108000-00012
  5. Ferrari A, Dileo P, Casanova M, et al (2003). Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution. Cancer, 98, 571-80. https://doi.org/10.1002/cncr.11550
  6. Hawkins WG, Hoos A, Antonescu CR, et al (2001). Clinicopathologic analysis of patients with adult rhabdomyosarcoma. Cancer, 91, 794-803. https://doi.org/10.1002/1097-0142(20010215)91:4<794::AID-CNCR1066>3.0.CO;2-Q
  7. Little DJ, Ballo MT, Zagars GK, et al (2002). Adult rhabdomyosarcoma: outcome following multimodality treatment. Cancer, 95, 377-88. https://doi.org/10.1002/cncr.10669
  8. National Comprehensive Cancer Network. Soft Tissue Sarcoma (Version 1.2015) [Online].
  9. Newton WA, Jr., Gehan EA, Webber BL, et al (1995). Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification--an Intergroup Rhabdomyosarcoma Study. Cancer, 76, 1073-85. https://doi.org/10.1002/1097-0142(19950915)76:6<1073::AID-CNCR2820760624>3.0.CO;2-L
  10. Parham DM, Ellison DA (2006). Rhabdomyosarcomas in adults and children: an update. Arch Pathol Lab Med, 130, 1454-65.
  11. Sezgin G, Acipayam C, Bayram I, et al (2015). Replacing actinomycin-D with Carboplatin for newly diagnosed rhabdomyosarcoma. Asian Pac J Cancer Prev, 16, 3351-4. https://doi.org/10.7314/APJCP.2015.16.8.3351
  12. Simon JH, Paulino AC, Ritchie JM, et al (2003). Presentation, prognostic factors and patterns of failure in adult rhabdomyosarcoma. Sarcoma, 7, 1-7. https://doi.org/10.1080/1357714031000114147
  13. Stock N, Chibon F, Binh MB, et al (2009). Adult-type rhabdomyosarcoma: analysis of 57 cases with clinicopathologic description, identification of 3 morphologic patterns and prognosis. Am J Surg Pathol, 33, 1850-9. https://doi.org/10.1097/PAS.0b013e3181be6209
  14. Sultan I, Qaddoumi I, Yaser S, et al (2009). Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2,600 patients. J Clin Oncol, 27, 3391-7. https://doi.org/10.1200/JCO.2008.19.7483

피인용 문헌

  1. Call for improved design and reporting in soft tissue sarcoma studies: A systematic review and meta-analysis of chemotherapy and survival outcomes in resectable STS pp.00224790, 2019, https://doi.org/10.1002/jso.25401